A new study reveals a previously overlooked biological mechanism that explains why many promising cancer drugs fail in later-stage clinical trials despite showing early success. Researchers discovered that certain tumors can activate alternative signaling pathways to bypass the specific cellular processes targeted by these drugs, a phenomenon known as ‘kinetic resistance.’ This finding challenges the long-held assumption that directly inhibiting a key cancer-driving protein is sufficient. The research, conducted on both cell cultures and animal models, suggests that future drug development needs to account for these adaptive escape routes, potentially through combination therapies or next-generation inhibitors. The study was published in the journal Nature Cell Biology. Read the full article at https://www.sciencedaily.com/releases/2026/04/260409101055.htm